Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00484601 | Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT03246685 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD | terminated | Phase 2 | 1 | HiberCell, Inc.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | terminated | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | terminated | Phase 2 | 157 | Novartis PharmaceuticalsINDUSTRY | 18 | Jul 24, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00126568 | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01488318 | Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma | terminated | Phase 2 | 21 | Julie E. Bauman, MD, MPHOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT01051791 | Phase II Study of RAD001 Head and Neck Cancer | terminated | Phase 2 | 13 | Julie E. Bauman, MD, MPHOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT01221753 | Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study | terminated | Phase 2 | 7 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | terminated | Phase 1 / Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02068157 | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer | terminated | Phase 2 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Oct 11, 2017 | clinicaltrials |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 2 | Apr 14, 2017 | clinicaltrials |
| NCT00392665 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity | terminated | Phase 1 / Phase 2 | 3 | Innate PharmaINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT01285635 | A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck | terminated | Phase 2 | 35 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT00272181 | Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer | terminated | Phase 2 | 15 | Sesen Bio, Inc.INDUSTRY | 2 | Dec 23, 2015 | clinicaltrials |
| NCT01694576 | NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation | terminated | Phase 2 | 10 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Jun 15, 2015 | clinicaltrials |
| NCT01305772 | Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN(TOP0901) | terminated | Phase 2 | 6 | Neal ReadyOTHER | 1 | Aug 29, 2014 | clinicaltrials |
| NCT01682031 | Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy | terminated | Phase 2 | 18 | Roswell Park Cancer InstituteOTHER | 2 | Aug 22, 2014 | clinicaltrials |
| NCT01403259 | SOX as Salvage Treatment in Nasopharyngeal Carcinoma | terminated | Phase 2 | 16 | Fudan UniversityOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer(FACT) | terminated | Phase 2 / Phase 3 | 80 | Mateon TherapeuticsINDUSTRY | 12 | Jun 9, 2014 | clinicaltrials |
| NCT00184028 | Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 2 | 12 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2014 | clinicaltrials |
| NCT00126607 | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT01015664 | Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 1 / Phase 2 | 11 | University of Tennessee Cancer InstituteOTHER | 1 | Dec 17, 2012 | clinicaltrials |
| NCT01415986 | Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers | terminated | Phase 2 | 1 | University of ArkansasOTHER | 1 | Dec 3, 2012 | clinicaltrials |
| NCT00805012 | Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC) | terminated | Phase 2 | 96 | Seoul National University HospitalOTHER | 1 | Jul 26, 2011 | clinicaltrials |
| NCT00647140 | Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer(DOPMET) | terminated | Phase 2 | 29 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 7, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Apr 16, 2019source: clinicaltrials